Urological cancers are thought to account for 19.5% of global cancer prevalence, with kidney, prostate, testicular, and bladder cancer. However, the key indications covered in this report ? accounting for the majority of that figure. Urological cancers affect the male and female urinary tract and the male reproductive organs. Prostate cancer is the most prevalent of these malignancies.
MARKET DYNAMICS
The urological cancer therapeutics drugs market is expected to grow due to the growing prevalence of chronic diseases and cancer. Moreover, the rise in government initiatives to enhance health care facilities and rising geriatric population propel the market growth in the forecast period.
MARKET SCOPE
The "Urological Cancer Therapeutics Drugs Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of urological cancer therapeutics drugs market with detailed market segmentation by type and application. The urological cancer therapeutics drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in urological cancer therapeutics drugs market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The urological cancer therapeutics drugs market is segmented on the basis of type and application. Based on type, the market is segmented as xofigo (radium ra 223 dichloride), jevtana (cabazitaxel), inlyta (axitinib), votrient (pazopanib hydrochloride), sutent (sunitinib malate), zytiga (abiraterone acetate), xtandi (enzalutamide), opdivo (nivolumab) and provenge (sipuleucel-T). On the basis of application, the market is categorized as hospital, medical research laboratory and others.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the urological cancer therapeutics drugs market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The urological cancer therapeutics drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting urological cancer therapeutics drugs market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the urological cancer therapeutics drugs market in these regions.
MARKET PLAYERS
The report covers key developments in the urological cancer therapeutics drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from urological cancer therapeutics drugs market are anticipated to have lucrative growth opportunities in the future with the rising demand for urological cancer therapeutics drugs in the global market. Below mentioned is the list of few companies engaged in the urological cancer therapeutics drugs market.
The report also includes the profiles of key players in urological cancer therapeutics drugs market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Abbott Laboratories
- AstraZeneca
- Bristol-Myers Squibb
- Dendreon Corporation
- GlaxoSmithKline plc
- Indevus Pharmaceuticals Inc
- Johnson and Johnson
- Novartis
- Pfizer
- Roche Healthcare
- Sanofi S.A.
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.